Managing Highly Insulin-Resistant Diabetes Mellitus: Weight Loss Approaches and Medical Management

References

• . Ogden CL, Carroll MD, McDowell MA, Flegal KM. Obesity among adults in the United States—no statistically significant chance since 2003–2004. NCHS Data Brief. 2007;(1):1–8
   Google Scholar
• . Knowler WC, Barrett-Connor E, Fowler SE,; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403
   PubMed Web of Science ®Google Scholar
• . Tuomilehto J, Lindström J, Eriksson JG,; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–1350
   PubMed Web of Science ®Google Scholar
• . Anderson JW, Konz EC. Obesity and disease management: effects of weight loss on comorbid conditions. Obes Res. 2001;(9 suppl 4):326S–334S
   Google Scholar
• . Blackburn G. Effect of degree of weight loss on health benefits. Obes Res. 1995;(3 suppl 2):211S–216S
   PubMedGoogle Scholar
• . Hellénius ML, de Faire U, Berglund B, Hamsten A, Krakau I. Diet and exercise are equally effective in reducing risk for cardiovascular disease. Results of a randomized controlled study in men with slightly to moderately raised cardiovascular risk factors. Atherosclerosis. 1993;103(1):81–91
   PubMedGoogle Scholar
• . Poston WS 2nd, Foreyt JP. Successful management of the obese patient. Am Fam Physician. 2000;61(12):3615–3622
   PubMed Web of Science ®Google Scholar
• . Sacks FM, Bray GA, Carey VJ,. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med. 2009;360(9):859–873
   PubMed Web of Science ®Google Scholar
• . McMillan-Price J, Petocz P, Atkinson F,. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial. Arch Intern Med. 2006;166(14):1466–1475
   PubMedGoogle Scholar
• . Noakes M, Keogh JB, Foster PR, Clifton PM. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr. 2005;81(6):1298–1306
   PubMed Web of Science ®Google Scholar
• . McLaughlin T, Carter S, Lamendola C,. Effects of moderate variations in macronutrient composition on weight loss and reduction in cardiovascular disease risk in obese, insulin-resistant adults. Am J Clin Nutr. 2006;84(4):813–821
   PubMedGoogle Scholar
• . Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. National Institutes of Health. Obes Res. 1998;(6 suppl 2):51S–209S
   PubMedGoogle Scholar
• . Anderson JW, Vichitbandra S, Qian W, Kryscio RJ. Long-term weight maintenance after an intensive weight-loss program. J Am Coll Nutr. 1999;18(6):620–627
   PubMed Web of Science ®Google Scholar
• . Quinn Rothacker D. Five-year self-management of weight using meal replacements: comparison with matched controls in rural Wisconsin. Nutrition. 2000;16(5):344–348
   PubMedGoogle Scholar
• . Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M, Frier HI. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord. 2003;27(5):537–549
   PubMed Web of Science ®Google Scholar
• . Metz JA, Stern JS, Kris-Etherton P,. A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: impact on cardiovascular risk reduction. Arch Intern Med. 2000;160(14):2150–2158
   PubMedGoogle Scholar
• . Metz JA, Kris-Etherton PM, Morris CD,. Dietary compliance and cardiovascular risk reduction with a prepared meal plan compared with a self-selected diet. Am J Clin Nutr. 1997;66(2):373–385
   PubMedGoogle Scholar
• . Williamson DA, Rejeski J, Lang W, Van Dorsten B, Fabricatore AN, Toledo K; Look AHEAD Research Group. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. Arch Intern Med. 2009;169(2):163–171
   PubMedGoogle Scholar
• . Kahn HS, Tatham LM, Rodriguez C, Calle EE, Thun MJ, Heath CW Jr. Stable behaviors associated with adults' 10-year change in body mass index and likelihood of gain at the waist. Am J Public Health. 1997;87(5):747–754
   PubMedGoogle Scholar
• . Heimendinger J, Van Duyn MA, Chapelsky D, Foerster S, Stables G. The national 5 A Day for Better Health Program: a large-scale nutrition intervention. J Public Health Manag Pract. 1996;2(2):27–35
   PubMedGoogle Scholar
• . Bloem CJ, Chang AM. Short-term exercise improves beta-cell function and insulin resistance in older people with impaired glucose tolerance. J Clin Endocrinol Metab. 2008;93(2):387–392
   PubMedGoogle Scholar
• . Lee CD, Blair SN, Jackson AS. Cardiorespiratory fitness, body composition, and all-cause and cardiovascular disease mortality in men. Am J Clin Nutr. 1999;69(3):373–380
   PubMed Web of Science ®Google Scholar
• . , Look AHEAD Research GroupPi-Sunyer X, Blackburn G, Brancati FL,. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30(6):1374–1383
   PubMed Web of Science ®Google Scholar
• . Wadden TA, West DS, Neiberg RH,; Look AHEAD Research Group.One-year weight losses in the Look AHEAD study: factors associated with success. Obesity (Silver Spring). 2009;17(4):713–722
   PubMed Web of Science ®Google Scholar
• . Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82( 1 suppl):222S–225S
   PubMed Web of Science ®Google Scholar
• . Wyatt HR, Peters JC, Reed GW, Barry M, Hill JO. A Colorado statewide survey of walking and its relation to excessive weight. Med Sci Sports Exerc. 2005;37(5):724–730
   PubMedGoogle Scholar
• . Heshka S, Greenway F, Anderson JW,. Self-help weight loss versus a structured commercial program after 26 weeks: a randomized controlled study. Am J Med. 2000;109(4):282–287
   PubMed Web of Science ®Google Scholar
• . Anderson JW, Grant L, Gotthelf L, Stifler LT. Weight loss and long-term follow-up of severely obese individuals treated with an intense behavioral program. Int J Obes (Lond). 2007;31(3):488–493
   PubMed Web of Science ®Google Scholar
• . Lecheminant JD, Kirk EP, Hall MA,. Impact of different levels of weight loss on blood pressure in overweight and obese women. Dis Manag. 2007;10(2):83–90
   PubMedGoogle Scholar
• . LeCheminant JD, Jacobsen DJ, Hall MA, Donnelly JE. A comparison of meal replacements and medication in weight maintenance after weight loss. J Am Coll Nutr. 2005;24(5):347–353
   PubMed Web of Science ®Google Scholar
• . Ma Y, Pagoto SL, Griffith JA,. A dietary quality comparison of popular weight-loss plans. J Am Diet Assoc. 2007;107(10):1786–1791
   PubMed Web of Science ®Google Scholar
• . Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293(1):43–53
   PubMed Web of Science ®Google Scholar
• . Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet. 1989;2(8672):1142–1145
   PubMed Web of Science ®Google Scholar
• . Kaplan LM. Pharmacological therapies for obesity. Gastroenterol Clin North Am. 2005;34(1):91–104
   PubMed Web of Science ®Google Scholar
• . Anderson JW, Schwartz SM, Hauptman J,. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial. Ann Pharmacother. 2006;40(10):1717–1723
   PubMedGoogle Scholar
• . Li Z, Maglione M, Tu W,. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532–546
   PubMed Web of Science ®Google Scholar
• . Buchwald H, Avidor Y, Braunwald E,. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–1737
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Bailey CJ. Metformin—an update. Gen Pharmacol. 1993;24(6):1299–1309
   PubMedGoogle Scholar
• . Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15(6):755–772
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333(9):541–549
   PubMed Web of Science ®Google Scholar
• . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–865
   PubMed Web of Science ®Google Scholar
• . Hermann LS, Scherstén B, Bitzén PO, Kjellström T, Lindgärde F, Melander A. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study. Diabetes Care. 1994;17(10):1100–1109
   PubMed Web of Science ®Google Scholar
• . Bailey CJ. Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab. 2005;7(6):675–691
   PubMedGoogle Scholar
• . Strowig SM, Raskin P. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus. Diabetes Obes Metab. 2005;7(6):633–641
   PubMedGoogle Scholar
• . Nathan DM, Buse JB, Davidson MB,; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Clar C, Royle P, Waugh N. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. PLoS One. 2009;4(7):e6112
   Google Scholar
• . Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820–825
   PubMed Web of Science ®Google Scholar
• . Johnson KH, O'Brien TD, Betsholtz C, Westermark P. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med. 1989;321(8):513–518
   PubMedGoogle Scholar
• . Hartter E, Svoboda T, Lell B,. Reduced islet-amyloid polypeptide in insulin-dependent diabetes mellitus. Lancet. 1990;335(8693):854
   PubMedGoogle Scholar
• . Hartter E, Svoboda T, Ludvik B,. Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia. 1991;34(1):52–54
   PubMed Web of Science ®Google Scholar
• . Ludvik B, Thomaseth K, Nolan JJ, Clodi M, Prager R, Pacini G. Inverse relation between amylin and glucagon secretion in healthy and diabetic human subjects. Eur J Clin Invest. 2003;33(4):316–322
   PubMedGoogle Scholar
• . Kong MF, King P, Macdonald IA,. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia. 1997;40(1):82–88
   PubMedGoogle Scholar
• . Chapman I, Parker B, Doran S,. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia. 2005;48(5):838–848
   PubMedGoogle Scholar
• . Whitehouse F, Kruger DF, Fineman M,. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care. 2002;25(4):724–730
   PubMed Web of Science ®Google Scholar
• . Ratner RE, Dickey R, Fineman M,. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. Diabet Med. 2004;21(11):1204–1212
   PubMed Web of Science ®Google Scholar
• . Ratner RE, Want LL, Fineman MS,. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther. 2002;4(1):51–61
   PubMedGoogle Scholar
• . Hollander PA, Levy P, Fineman MS,. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26(3):784–790
   PubMed Web of Science ®Google Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143(8):559–569
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Duran S, Kim D,. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50(2):259–267
   PubMed Web of Science ®Google Scholar
• . Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care. 2007;30(11):2767–2772
   PubMed Web of Science ®Google Scholar
• . Lane WS, Cochran EK, Jackson JA,. High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract. 2009;15(1):71–79
   PubMed Web of Science ®Google Scholar
• . Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28(5):1240–1244
   PubMedGoogle Scholar
• . Jørgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract. 2000;50(3):161–167
   PubMedGoogle Scholar
• . Garg R, Johnston V, McNally PG, Davies MJ, Lawrence IG. U-500 insulin: why, when and how to use in clinical practice. Diabetes Metab Res Rev. 2007;23(4):265–268
   PubMedGoogle Scholar
• . Mäkimattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia. 1999;42(4):406–412
   PubMedGoogle Scholar
• . Ballani P, Tran MT, Navar MD, Davidson MB. Clinical experience with U-500 regular insulin in obese, markedly insulin-resistant type 2 diabetic patients. Diabetes Care. 2006;29(11):2504–2505
   PubMedGoogle Scholar